Philadelphia Researchers Develop ‘Cyborg’ Pancreas to Combat Diabetes

Researchers at the University of Pennsylvania, in collaboration with engineers from Harvard University, have developed a groundbreaking “cyborg” pancreas. This innovation involves wiring lab-grown mini pancreases with ultrathin electronics, aimed at enhancing the maturity and function of insulin-producing cells in a manner that mimics natural pancreatic islets. The findings, published in the journal Science on February 19, 2026, offer promising avenues for improving cell-based transplants for individuals with Type 1 diabetes.

Innovative Technology for Cell Development

The research team has created a stretchable mesh device that is thinner than a human hair. This mesh is integrated into developing pancreatic tissue, allowing it to flex as the organoid expands. According to Penn Medicine, this configuration enables researchers to monitor cellular activity at single-cell resolution. The mesh not only detects electrical signals but also delivers controlled pulses to stimulate the cells, creating a more natural environment for their development.

By mimicking meal-time glucose levels, the team discovered that immature pancreatic cells adopted circadian-like electrical patterns. This synchronization improved the cells’ responsiveness to glucose challenges. The researchers utilized the mesh’s built-in actuators to deliver targeted electrical stimuli, which increased the expression of genes related to energy metabolism and cell communication. The results indicate a significant enhancement in the cells’ ability to release hormones effectively.

Future Applications and Research Directions

Juan Alvarez, an assistant professor at Penn Medicine, described the device as “bionic,” likening its function to that of a pacemaker for pancreatic tissue. The research team is considering two main strategies moving forward: using electrical stimulation to prepare lab-grown pancreatic islets for transplantation, or keeping the sensors in place to monitor and enhance the grafts post-implantation. The researchers emphasize the need for further testing to assess long-term safety, durability, and compatibility with the immune system before advancing to human trials.

The study’s co-first authors, Qiang Li and Ren Liu, along with co-senior authors Jia Liu and Juan R. Alvarez-Dominguez, represent both Harvard SEAS and the Perelman School of Medicine. Funding for this research was provided by the National Institutes of Health (NIH), JDRF, and the JPB Foundation, among other sources. As the team prepares for preclinical testing, they aim to determine whether this approach can be scaled for human application and how well the bioelectronic scaffold withstands immune responses and long-term usage.

This innovative research represents a significant step toward enhancing treatments for diabetes, potentially transforming the way pancreatic cell transplants are approached in the future.